DMAA
Drugs Made In America Acquisition Corp.
Next earnings Aug 3, 2026
$10.64
▲ 0.00%$10.64▲ +4.42%
over 1Y
L $10.18EODHDH $10.64
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-0.0%
1M+0.4%
3M+1.2%
YTD+2.5%
1Y+4.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -1.00x).
Liabilities / equity -1.00x · latest
Drugs Made In America Acquisition Corp. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY25 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$2.82M |
| Net income | $5.94M |
| Diluted EPS | — |
| Net margin | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$359M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield1.7%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$6.14K
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-04-01). Worth a closer look.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-26open ↗10-QPeriod ending 2026-03-312026-05-14open ↗SCHEDULE 13GFiling2026-05-14open ↗425Filing2026-05-05open ↗8-KPeriod ending 2026-04-292026-05-05open ↗8-KPeriod ending 2026-04-272026-05-01open ↗8-KPeriod ending 2026-04-222026-04-28open ↗DEFR14AFiling2026-04-16open ↗10-KPeriod ending 2025-12-312026-04-15open ↗DEF 14APeriod ending 2026-04-272026-04-14open ↗8-KPeriod ending 2026-04-072026-04-08open ↗NT 10-KPeriod ending 2025-12-312026-04-01open ↗
Frequently asked
- Is Drugs Made In America Acquisition Corp. (DMAA) a buy?
- DMAA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.00x).
- What is Drugs Made In America Acquisition Corp.'s quality score?
- DMAA scores 36.666666666666664/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002028614, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:24:06 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.